MDS Foundation shared on X:
“On July 26th, 2024, the National Comprehensive Cancer Network updated its Clinical Practice Guidelines in Oncology for MDS. RYTELO™ (imetelstat) is now recommended as a Category 1 and 2A treatment for symptomatic anemia in patients with lower-risk MDS.”
Source : MDS Foundation/X